{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:09Z","timestamp":1792786149987,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This research was funded by the Chung Shan Medical University Hospital","award":["grant number: CSH-2024-A-022"],"award-info":[{"award-number":["grant number: CSH-2024-A-022"]}],"id":[{"id":"https:\/\/ror.org\/01abtsn51","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:p>\n                    The coexistence of cancer and atrial fibrillation (AF) significantly exacerbates the risk of stroke recurrence and associated complications. The complex interplay between these conditions elevated the thromboembolic burden, bleeding risk, and all-cause mortality. However, the optimal antithrombotic strategy for secondary prevention in this population remains ill-defined. This study aims to compare the therapeutic outcomes of anticoagulant versus antiplatelet therapies in cancer patients with AF. This retrospective study identified ischemic stroke (IS) patients with both cancer and AF at a single medical center from January 2018 to June 2023. Patients receiving antithrombotic treatment for &lt;1 month were excluded. The outcomes of interest included all-cause mortality, major bleeding, and recurrent ischemic events. Kaplan\u2013Meier survival analysis and Cox regression models were utilized to compare outcomes between the 2 treatment groups. The cohort comprised 53 patients, with 38 receiving anticoagulants, and 15 receiving antiplatelets. Antiplatelet therapy was associated with a significantly higher mortality risk compared to anticoagulant therapy (hazard ratio [HR]:3.72; 95% confidence interval [CI]:1.39\u20139.94,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.009). There were no significant differences between the groups regarding recurrent IS events (HR: 0.035; 95% CI: 0\u201369.96;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.388) or major bleeding events (HR: 1.44; 95% CI: 0.38\u20135.46\n                    <jats:italic toggle=\"yes\">, P<\/jats:italic>\n                    \u2005=\u2005.594). This study suggests that anticoagulant therapy is associated with superior survival outcomes without an increased risk of bleeding compared to antiplatelet treatment. These findings may assist clinical decision-making regarding thromboembolism management and bleeding risk in IS patients with concurrent cancer and AF.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047883","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:01:25Z","timestamp":1773043285000},"page":"e47883","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic agents for secondary ischemic stroke prevention in cancer patients with atrial fibrillation: A tertiary medical center retrospective study"],"prefix":"10.1097","volume":"105","author":[{"given":"Ching-Wei","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."},{"name":"Department of Neurology, Chung Shan Medical University, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Fu","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."},{"name":"Department of Neurology, Chung Shan Medical University, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6319-4218","authenticated-orcid":false,"given":"Hsin Yi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, R.O.C."},{"name":"Department of Neurology, Chung Shan Medical University, Taichung, Taiwan, R.O.C."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2019.02278","article-title":"Cancer-related stroke: an emerging subtype of ischemic stroke with unique pathomechanisms.","volume":"22","author":"Bang","year":"2020","journal-title":"J Stroke"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-019-13120-6","article-title":"Stroke among cancer patients.","volume":"10","author":"Zaorsky","year":"2019","journal-title":"Nat Commun"},{"key":"R4-20261009","first-page":"1039","article-title":"Stroke and cancer \u2013 a complicated relationship.","volume":"2","author":"Dearborn","year":"2014","journal-title":"J Neurol Transl Neurosci"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.acvd.2023.11.007","article-title":"Cancer-related arterial thromboembolic events.","volume":"117","author":"Pernod","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association.","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study.","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncol"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/eurheartj\/ehae222","article-title":"Coexisting atrial fibrillation and cancer: time trends and associations with mortality in a nationwide Dutch study.","volume":"45","author":"Chen","year":"2024","journal-title":"Eur Heart J"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"R10-20261009","first-page":"48","article-title":"Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.","volume":"10","author":"Nardi","year":"2024","journal-title":"Cardiooncology"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"e029423","DOI":"10.1161\/JAHA.123.029423","article-title":"Common cancer types and risk of stroke and bleeding in patients with nonvalvular atrial fibrillation: a population-based study in England.","volume":"12","author":"Ajabnoor","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12883-023-03208-4","article-title":"Bleeding risk and mortality according to antithrombotic agents\u2019 exposure in cancer-related stroke patients: nationwide population-based cohort study in South Korea.","volume":"23","author":"Choi","year":"2023","journal-title":"BMC Neurol"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA(2)DS(2)\u2013VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer.","volume":"25","author":"D\u2019Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-medicare analysis.","volume":"43","author":"Guha","year":"2022","journal-title":"Eur Heart J"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","article-title":"Arterial thromboembolism in patients with AF and CHA(2)DS(2)\u2013VASc score 0\u20132 with and without cancer.","volume":"5","author":"Leader","year":"2023","journal-title":"JACC CardioOncol"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management.","volume":"28","author":"Boriani","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"100096","DOI":"10.1016\/j.rpth.2023.100096","article-title":"Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice.","volume":"7","author":"Chu","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1161\/STROKEAHA.120.033470","article-title":"Clinical outcomes in atrial fibrillation patients with a history of cancer treated with non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.","volume":"52","author":"Chan","year":"2021","journal-title":"Stroke"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11239-019-01974-y","article-title":"Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.","volume":"50","author":"Brunetti","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-017-9683-z","article-title":"Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?","volume":"36","author":"Wojtukiewicz","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial.","volume":"75","author":"Navi","year":"2018","journal-title":"JAMA Neurol"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"1530775","DOI":"10.3389\/fneur.2025.1530775","article-title":"Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer.","volume":"16","author":"Kielkopf","year":"2025","journal-title":"Front Neurol"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/jamaneurol.2024.2404","article-title":"Apixaban vs aspirin in patients with cancer and cryptogenic stroke: a post hoc analysis of the ARCADIA randomized clinical trial.","volume":"81","author":"Navi","year":"2024","journal-title":"JAMA Neurol"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.","volume":"27","author":"Martinez-Majander","year":"2020","journal-title":"Eur J Neurol"},{"key":"R27-20261009","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1158\/1055-9965.EPI-23-0866","article-title":"Patterns of anticoagulation use and all-cause of mortality in cancer patients with atrial fibrillation.","volume":"33","author":"Han","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"e2325283","DOI":"10.1001\/jamanetworkopen.2023.25283","article-title":"Comparative effectiveness of anticoagulants in patients with cancer-associated thrombosis.","volume":"6","author":"Riaz","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.5853\/jos.2016.00570","article-title":"Hypercoagulability and mortality of patients with stroke and active cancer: the OASIS-CANCER study.","volume":"19","author":"Lee","year":"2017","journal-title":"J Stroke"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10741-019-09844-8","article-title":"Efficacy and safety of oral anticoagulants in atrial fibrillation patients with cancer-a network meta-analysis.","volume":"25","author":"Yang","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus later anticoagulation for stroke with atrial fibrillation.","volume":"388","author":"Fischer","year":"2023","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:08:57Z","timestamp":1791569337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047883","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"assertion":[{"value":"2025-10-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}